| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
998 |
471 |
$54K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,157 |
632 |
$43K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,117 |
514 |
$20K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
985 |
494 |
$18K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
215 |
104 |
$15K |
| 36556 |
|
68 |
54 |
$3K |
| 99223 |
Prolong inpt eval add15 m |
29 |
23 |
$2K |
| 99254 |
|
14 |
13 |
$929.60 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
16 |
15 |
$600.01 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
950 |
458 |
$436.84 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
16 |
15 |
$430.39 |